Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More

Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More
Congruence Therapeutics, a pioneering biotechnology company focused on developing novel small molecule correctors, has successfully closed a significant $39.5 million…
Read More